You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

92 Results
Document
May 2019
Guidelines and Advice
Status: Current
Version: 1
Feb 2022
Guidelines and Advice
Status: In-Review
ID: 7-14
Version: 3
Dec 2018
Guidelines and Advice
Status: Archived
ID: 1-6
Sep 2011
Symptom Management
Guidelines and Advice
Status: Current
ID: SCT 5
Aug 2013
Guidelines and Advice
Status: Current
Mar 2019
Guidelines and Advice
Status: Current
ID: 19-5
Version: 2
Jul 2024
Guidelines and Advice
Status: Current
Version: 1
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Epcoritamab (Outpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma
High Cost Therapy Funding Program
    Epcoritamab (Inpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
epcoritamab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2024

Pages